Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a telehealth program help older adults prevent diabetes?

NCT ID NCT05166785

Prevention Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a diabetes prevention program delivered via telehealth works as well as the same program done in person for adults aged 65 and older with prediabetes. About 238 participants will be randomly assigned to either a telehealth or in-person group, and researchers will track changes in weight and blood sugar levels over 12 months. The goal is to find effective ways to help the growing older adult population reduce their risk of developing diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diabetes Prevention Program (DPP) tailored for older adults, delivered via telehealth or in-person
What this could lead to
If successful, this could show that a telehealth version of the diabetes prevention program works as well as in-person sessions for older adults, making it easier for many to access and reduce their diabetes risk.
What could go wrong
This is a relatively small study (238 participants) comparing two delivery methods, not testing a new drug. Results may not apply to all older adults, and adherence or weight loss might differ between groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

238 people

The number who actually took part.

Started

Oct 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 65 years and older * Diagnosis of pre-diabetes (A1c between 5.7-6.4%, fasting glucose between 100-125 mg/dL, or oral glucose tolerance test between 140-199 mg/dL within past 12 months) * BMI of greater than or equal to 30 * English-speaking * Under the care of a Primary care provider (PCP) in the NYU Langone Health system * Able to travel to NYU Langone for in-person evaluations * Access to a telephone * Informed consent Exclusion Criteria: * Prevalent diabetes or end-stage renal disease * Prior participation in the Diabetes Prevention Program * A documented current history of active psychosis or other cognitive issues via International Classification of Diseases (ICD) -10 codes * Taking FDA-approved weight loss medications * PCP stating that patient should not participate * Inability to communicate due to severe, uncorrectable hearing loss or speech disorder * Severe visual impairment that precludes completion of assessments and/or intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-diabetes

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.